---
schema_version: "secwatch.filing_event.v1"
accession: "0001563665-22-000019"
form_type: "8-K"
ticker: "HRGN"
cik: "0001563665"
company_name: "Harvard Apparatus Regenerative Technology, Inc."
filed_at: "2022-12-23T23:59:59+00:00"
generated_at: "2026-06-20T23:20:56.594344+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Biostage Announces Publication Showing Rapid Esophageal Regeneration in Pigs

## Summary
- Publication in Journal of Immunology and Regenerative Medicine describes regeneration after Biostage Esophageal Implant in nine pigs with full circumferential replacement.
- All animals regenerated a continuous biological conduit by 28 days; some as early as 14 days.
- Regeneration time compares favorably with FDA-approved clinical trial primary endpoint of 90 days.
- Biostage expects to initiate patient recruitment in first clinical trial in early 2023.
- Study also quantified epithelialization and fate of adipose-derived mesenchymal stromal cells.

## SEC filing metadata
- accession: 0001563665-22-000019
- form_type: 8-K
- ticker: HRGN
- cik: 0001563665
- company_name: Harvard Apparatus Regenerative Technology, Inc.
- filed_at: 2022-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563665/000156366522000019/0001563665-22-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563665/000156366522000019/tmb-20221223x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001563665-22-000019
- JSON: https://secwatch.observer/filing/0001563665-22-000019.json
- Plain text: https://secwatch.observer/filing/0001563665-22-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.